儿童CD19 CAR-T细胞治疗相关B细胞再生障碍的临床意义和对策

doi:10.12372/jcp.2024.24e0577

Abstract

Abstract:

B cell aplasia (BCA) is a common adverse side effect in pediatric patients with B-acute lymphoblastic leukemia (B-ALL) following CD19-chimeric antigen receptor T-cell (CD19 CAR-T) therapy. The duration of BCA has an impact on the immune status and prognosis of patients. A thorough understanding of BCA helps physicians choose treatment plans in a scientific, normative, and reasonable manner, reducing the risk of infection in pediatric leukemia patients after CAR-T treatment and improving their prognosis and quality of life.

Key words: B-acute lymphoblastic leukemia, CD19 CAR-T, B cell aplasia, child

LU Jun. The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients[J].Journal of Clinical Pediatrics, 2024, 42(7): 578-582.

References 30

[1]	Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. doi: 10.3324/haematol.2020.247031 pmid: 33054110
[2]	Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 449-459.
[3]	Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial[J]. J Clin Oncol, 2023, 41(9): 1664-1669.
[4]	Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL[J]. Blood, 2019, 134(26): 2361-2368. doi: 10.1182/blood.2019001641 pmid: 31650176
[5]	Maria Gabelli, Macarena Oporto-Espuelas, Saskia Burridge, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy[J]. Blood Adv, 2024, 8(8): 1959-1963.
[6]	Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia[J]. J Immunother Cancer, 2021, 9: e002287.
[7]	Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386.
[8]	Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. doi: 10.1182/blood-2017-07-793760 pmid: 29038338
[9]	Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20: 31-42. doi: S1470-2045(18)30864-7 pmid: 30518502
[10]	Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees[J]. J Allergy Clin Immunol, 2022, 149(5): 1525-1560. doi: 10.1016/j.jaci.2022.01.025 pmid: 35176351
[11]	Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448.
[12]	Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. doi: 10.1182/blood-2017-07-793760 pmid: 29038338
[13]	Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma[J]. Blood Adv, 2021, 5(1): 143-155. doi: 10.1182/bloodadvances.2020002732 pmid: 33570626
[14]	Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy[J]. Blood Adv, 2022, 6(7): 2045-2054.
[15]	Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1): 45-56.
[16]	Wu X, Cao Z, Chen Z, et al. Infectious complications in pediatric patients undergoing CD19⁺CD22⁺ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia[J]. Clin Exp Med, 2024, 24(1): 87.
[17]	Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386.
[18]	Arnold DE, Maude SL, Callahan CA, et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients[J]. Pediatr Blood Cancer, 2020, 67(3): e28092.
[19]	Hill JA, Giralt S, Torgerson TR, et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy[J]. Blood Rev, 2019, 38: 100596.
[20]	Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy[J]. Pediatr Blood Cancer, 2018, 65(4): 10.1002/pbc.26914.
[21]	Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper[J]. Infection, 2021, 49(2): 215-231.
[22]	Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells[J]. Biol Blood Marrow Transplant, 2020, 26(1): 26-33.
[23]	Bhella S, Majhail NS, Betcher J, et al. Choosing wisely BMT: American society for blood and marrow transplantation and Canadian blood and marrow transplant group's list of 5 tests and treatments to question in blood and marrow transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(5): 909-913.
[24]	Dourthe ME, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagen-lecleucel for B-cell acute lymphoblastic leukemia[J]. Leukemia, 2021, 35(12): 3383-3393.
[25]	Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia[J]. J Clin Oncol, 2023, 41(2): 354-363.
[26]	Jacoby E. The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia[J]. Bone Marrow Transplant, 2019, 54(Suppl 2): 810-814.
[27]	Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2): 460-466.
[28]	Gabelli M, Oporto Espuelas M, Bonney D, et al. ALL maintenance treatment for early loss of B-cell aplasia after tisagenlecleucel therapy[J]. Blood, 2021, 138(suppl 1): 3859.
[29]	Shiqi L, Jiasi Z, Lvzhe C, et al. Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T[J]. Mol Ther Oncolytics, 2023, 29: 107-117.
[30]	Holland EM, Molina JC, Dede K, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation[J]. J Immunother Cancer, 2022, 10(5): e004483.

The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 30

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.